Samples were curated based on whether their genetic mutations were predictors of poor prognosis (e.g., KMT2A-rearrangement, NUP98::NSD1, PICALM::MLLT10, or DEK::NUP214), were highly prevalent (RUNX1::RUNX1T1), or were enriched in MPAL (e.g., ZNF384::EP300 in B/myeloid MPAL [33]) (Table 1). This evidence concerns the gene KMT2A and mixed phenotype acute leukemia.